Enveric Biosciences Inc (ENVB) — Cash Flow-to-Debt Ratio
Enveric Biosciences Inc (ENVB) has a Cash Flow-to-Debt Ratio of -2.29x as of September 2025, meaning its operating cash flow of $-2.07 Million could theoretically repay -2% of its total liabilities ($905.88K) in one year. See free cash flow generation of Enveric Biosciences Inc to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Enveric Biosciences Inc Cash Flow-to-Debt Ratio (1994–2024)
Historical debt coverage capacity for Enveric Biosciences Inc across 31 annual periods. Also explore ENVB net assets growth trend to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Enveric Biosciences Inc (1994–2024)
Year-by-year debt coverage analysis for Enveric Biosciences Inc. For market capitalisation and broader financial context, see market value of Enveric Biosciences Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -5.19x | $-7.73 Million | $1.49 Million | ▲ +13.8% |
| 2023 | -6.01x | $-14.09 Million | $2.34 Million | ▼ -40.2% |
| 2022 | -4.29x | $-17.15 Million | $4.00 Million | ▼ -65.3% |
| 2021 | -2.60x | $-11.46 Million | $4.41 Million | ▲ +54.5% |
| 2020 | -5.71x | $-3.89 Million | $681.25K | ▼ -12573.4% |
| 2019 | -0.05x | $-647.86K | $14.38 Million | ▲ +66.9% |
| 2018 | -0.14x | $-2.57 Million | $18.88 Million | ▼ -62.4% |
| 2017 | -0.08x | $-2.74 Million | $32.75 Million | ▲ +13.8% |
| 2016 | -0.10x | $-2.70 Million | $27.84 Million | ▲ +64.1% |
| 2015 | -0.27x | $-3.67 Million | $13.58 Million | ▲ +94.4% |
| 2014 | -4.82x | $-43.16K | $8.96K | ▼ -450.2% |
| 2013 | -0.88x | $-21.63K | $24.70K | ▲ +9.5% |
| 2012 | -0.97x | $-24.85K | $25.67K | ▲ +42.9% |
| 2011 | -1.70x | $-30.35K | $17.89K | ▼ -111.2% |
| 2010 | -0.80x | $-40.67K | $50.64K | ▲ +85.3% |
| 2009 | -5.48x | $-65.04K | $11.87K | ▲ +22.6% |
| 2008 | -7.08x | $-150.19K | $21.21K | ▼ -202.8% |
| 2007 | 6.89x | $329.93K | $47.90K | ▲ +296.0% |
| 2006 | -3.51x | $-305.91K | $87.08K | ▼ -145.8% |
| 2005 | -1.43x | $-256.57K | $179.52K | ▼ -376.9% |
| 2004 | 0.52x | $343.94K | $666.31K | ▲ +150.8% |
| 2003 | -1.02x | $-253.97K | $249.77K | ▼ -478.6% |
| 2002 | 0.27x | $85.14K | $317.01K | ▲ +127.0% |
| 2001 | -0.99x | $-339.68K | $341.54K | ▼ -649.9% |
| 2000 | 0.18x | $145.84K | $806.35K | ▲ +136.7% |
| 1999 | -0.49x | $-665.38K | $1.35 Million | ▲ +59.8% |
| 1998 | -1.22x | $-3.00 Million | $2.45 Million | ▲ +45.7% |
| 1997 | -2.25x | $-3.70 Million | $1.64 Million | ▲ +58.3% |
| 1996 | -5.41x | $-4.72 Million | $873.32K | ▼ -5.2% |
| 1995 | -5.14x | $-3.60 Million | $700.00K | ▼ -478.6% |
| 1994 | -0.89x | $-800.00K | $900.00K | — |